The order was signed on June 16 in Asunción by Dr. Julio Borba, Paraguay Minister of Health and Social Welfare, and Jon Harrison, Vaxxinity Chief Strategy officer. Ambassador José Han, Taiwan's Ambassador to Paraguay, was also present (pictured).
The UB-612 vaccine is expected to be delivered later this summer, pending issuance of an EUA by the TFDA and subsequent registration by Paraguay's National Health Surveillance Authority (DINAVISA).
As the Ministry of Health and Welfare noted a leadership shown on June 16 by the government of Paraguay guarantees that Paraguay will be one of the first countries in the world to receive UB-612 once it is issued an EUA.
Vaxxinity, in close collaboration with its partner, UBI-Asia, is completing a large Phase 2 clinical trial of UB-612 in Taiwan, with support from Taiwan's Ministry of Health and Welfare, and will soon begin its Phase 2/3 efficacy trial in India in partnership with Aurobindo.
Vaxxinity has also announced a global logistics partnership with Maersk, the world's largest shipping and integrated logistics provider, that creates a framework for all transportation and supply chain services that will be needed to deliver UB-612 around the world.
The Vaxxinity UB-612 vaccine is the first Multitope protein/synthetic peptide vaccine to fight the SARS-CoV-2 virus. The UB-612 vaccine elicits broad humoral or cellular immune responses against several viral proteins to protect against COVID-19.
Headquartered in Dallas, TX, with partners in the United States, Latin America, Europe, and Asia, Vaxxinity's proprietary Multitope technology platform has enabled the innovation of synthetic peptide vaccines designed to treat and prevent infectious diseases, including COVID-19, and chronic diseases, such as Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Unlike vaccines designed to prevent exogenous diseases, Vaxxinity's chronic disease pipeline is designed to train the body to produce its own antibodies against internal targets of disease.
This comes with practical administrative and cost advantages versus monoclonal antibodies, meaning that Vaxxinity may, if approved, offer infrequent IM injection versus frequent IV infusion, and lower costs.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients